---
title: "Trump administration moves target international researchers, visas, kratom scheduling, and pharma i"
id: "news-news-stat-6b9b55c042537251a1ed8883"
canonical_url: "https://medichelpline.com/news/news-news-stat-6b9b55c042537251a1ed8883"
content_type: "medical_news_article"
category: "Health"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/10/13/health-news-trump-admin-clamps-down-on-international-researchers/?utm_campaign=rss"
published_at: "2026-10-13T11:46:54.000Z"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Trump administration moves target international researchers, visas, kratom scheduling, and pharma i
## Metadata & Source Attribution
- **Canonical URL:** https://medichelpline.com/news/news-news-stat-6b9b55c042537251a1ed8883
- **Category:** [Health](https://medichelpline.com/news/health.md)
- **Reporting Source:** STAT News
- **Original Source URL:** [Read Original Article](https://www.statnews.com/2026/10/13/health-news-trump-admin-clamps-down-on-international-researchers/?utm_campaign=rss)
- **Published At:** 2026-10-13T11:46:54.000Z
## Executive Summary & Key Highlights
- In early October 2026 the Department of Homeland Security proposed a $70,000 fee for a work-authorization program commonly used by foreign students, and the Labor Department opened probes into nine universities — including Harvard, Stanford, and Yale — over alleged J-1 visa fraud. These actions target **international researchers** who form a large part of the U.S. biomedical workforce. - DHS is also litigating to impose a four-year cap on stays for graduate students and postdocs and is seeking to reinstate a plan for $100,000 fees on H-2B visas for high-skill workers in fields such as biotech. None of these measures have taken effect yet. - A survey by the Association of American Universities found domestic applications to U.S. Ph.D. programs rose 3% this year while international applications fell 21%, suggesting deterrent effects from the administration’s moves. - A Cochrane review summarized by STAT reporters found that **pharmaceutical** gifts and meals increase inappropriate prescribing; pharmaceutical companies spent more than $250 million on meals in 2022, according to STAT’s reporting. - The DEA revised its proposed temporary scheduling for certain kratom derivatives, changing thresholds for 7-hydroxymitragynine (7-OH) and mitragynine pseudoindoxyl (MGPI) to focus on concentration within products rather than total amounts, a shift welcomed by the American Kratom Association. - Wellcome Global Monitor data reported that 52% of Americans say they have “a lot” of trust in science, higher than global averages, and 45% of Americans say they would get vaccines recommended by a nurse or doctor “right away.” - STAT pieces also examined cultural issues in medicine, including a column on “learned helplessness” among physicians and ongoing coverage of drug safety, AI in health, and policy developments.
## In-Depth Reporting & Editorial Analysis
## Administration actions put international researchers under pressure Over two days in early October 2026, federal agencies announced a series of measures aimed at foreign students and scholars who make up a substantial portion of the United States’ biomedical research workforce. On Wednesday, the Department of Homeland Security put forward a proposed $70,000 fee for a work-authorization program that many foreign students rely on to gain professional experience. The following day, the Labor Department said it was investigating nine universities — including Harvard, Stanford, and Yale — for alleged fraud related to J-1 visas awarded to postdoctoral researchers. These announcements came while DHS is fighting in court to impose a four-year cap on stays in the U.S. by graduate students and postdocs. The department is also trying to revive earlier plans to impose $100,000 fees for H-2B visas, which are used by foreign workers in high-skill fields such as biotech. None of these policy changes are in effect, but experts and university leaders say the repeated attempts have an immediate impact: prospective international applicants are reconsidering coming to the U.S. A survey from the Association of American Universities found that domestic applications to U.S. Ph.D. programs rose 3% this year, while international applications dropped 21%. Immigration attorney Elizabeth Goss described the moves as an intentional deterrent, saying the government appears to be signaling: don’t come here. ### Why these measures matter for U.S. research International students and scholars supply an outsized share of talent and labor to laboratories, classrooms, and companies across the country. Changes that raise the cost or legal risk of hiring or training foreign researchers could alter the composition and productivity of the biomedical workforce. Even proposals that have not been implemented can influence behavior: the AAU application shifts suggest prospective students may be choosing other countries or delaying applications in response to policy uncertainty. The potential consequences are practical as well as reputational. If fewer international researchers accept positions in the U.S., institutions could face delays on research projects, gaps in specialized expertise, and slower translation of scientific advances. The administration’s legal battles and fee proposals are also likely to produce litigation and political pushback from universities and scientific organizations. ## Pharma meals and gifts linked to inappropriate prescribing A Cochrane review summarized by STAT writers examined dozens of prior studies on industry payments to clinicians. The review found that gifts, including **meals**, and other payments doctors receive from drugmakers are associated with higher rates of inappropriate prescribing, which can increase health care costs. STAT reporting noted a clear relationship: the more meals a doctor received from a company, the more of that company’s drug the doctor prescribed. STAT also reported that pharmaceutical companies spent over $250 million on meals in 2022. Those expenditures feed concerns about how industry influence shapes clinical decisions and health system spending. The Cochrane review underscores ongoing debates about disclosure, restrictions on industry marketing, and how to protect prescribing practices from commercial influence. ## DEA refines approach to regulating kratom derivatives The Drug Enforcement Administration adjusted its proposed temporary scheduling for certain kratom-related compounds. Earlier proposals would have designated 7-hydroxymitragynine (**7-OH**) above a potency threshold as Schedule I and would have placed three synthetic kratom derivatives, including mitragynine pseudoindoxyl (**MGPI**), into Schedule I at any level. The DEA’s notice of intent changed course by setting new thresholds that apply to 7-OH and MGPI based on the concentration in a product rather than total amount, and the thresholds apply to the compounds individually or in combination. That change addressed concerns raised by the American Kratom Association, which argued that the original scheduling approach could have inadvertently criminalized natural leaf products that contain trace amounts of MGPI. The association welcomed the DEA’s revision as resolving its lawsuit against the earlier MGPI scheduling. Still, some drug policy advocates and lawmakers have urged broader limits on all kratom products, including natural leaf preparations. Experts remain divided about the best long-term regulatory strategy for kratom and its derivatives. STAT reporting noted uncertainty about when final scheduling decisions will be made, and a recent government watchdog report concluded that both the DEA and the Department of Health and Human Services lack adequate policies and procedures on drug scheduling. ## Public attitudes and culture in medicine: context and signals Separate data and commentary in STAT this week paint a mixed picture of public trust and professional culture. The Wellcome Global Monitor found that 52 percent of Americans report having “a lot” of trust in science — substantially higher than the global average reported in the poll. Americans were also more likely than people in some peer countries to say they would take recommended vaccines “right away.” On the professional side, a new column examined the experience of physicians in training and early career doctors who confront hierarchical and bureaucratic systems. The column argued that persistent deferential treatment and limited autonomy in residency programs can produce “learned helplessness,” a state in which clinicians feel they lack power to change unfavorable conditions. That dynamic may compound frustrations around administrative burdens, legal threats, and metrics-driven oversight. ## What’s next: litigation, rulemaking, and continued scrutiny At present, the administration’s proposals and investigations have not been finalized. DHS continues to litigate the proposed four-year cap on graduate student and postdoc stays, and other fee proposals remain subject to administrative rulemaking and legal challenges. The Labor Department’s investigations into university J-1 programs could lead to additional regulatory action or enforcement, but STAT’s reporting did not provide final outcomes for those probes. On kratom, the DEA’s notice of intent set a new direction for possible scheduling, but STAT noted it is unclear when the final scheduling will be settled. The governance of drug scheduling is under scrutiny after a watchdog report found procedural weaknesses at DEA and HHS. More broadly, the accumulation of administrative proposals, investigations, and litigation appears to be shaping behavior now, even before any formal policy takes effect. Universities, researchers, and prospective students are monitoring developments closely, and early signs — such as the AAU admissions survey — suggest measurable shifts in international interest. ## Further reading and sources This roundup draws on reporting and analysis published by STAT on Oct. 13, 2026, including articles by Amanda Erickson, Theresa Gaffney, and Jonathan Wosen. The piece references a DHS proposal for a $70,000 fee, Labor Department investigations of nine universities, DHS litigation over a four-year cap on stays for graduate students and postdocs, attempted H-2B fee proposals, an AAU admissions survey showing a 21% drop in international Ph.D. applications, a Cochrane review summarized in STAT on pharmaceutical gifts and prescribing, DEA notices regarding **kratom** derivatives including **7-OH** and **MGPI**, and the Wellcome Global Monitor findings on American trust in science. Where STAT’s stories did not report final outcomes or precise timelines, those details were not available in the source coverage.
## Navigation
- [← Back to Health News](https://medichelpline.com/news/health.md)
- [← All Medical News Categories](https://medichelpline.com/news.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.